Company Performance Metrics
Kannan Rangaramanujam: CTO & Co-Founder- Sujatha Kannan: Co-Founder
Orpheris is a clinical stage neuroscience company leveraging a novel platform technology from Johns Hopkins that enables the selective delivery of therapeutic agents across the blood barrier into reactive microglial cells. In a number of neurodegenerative diseases such as ALS, Parkinson's, and Alzheimer's, reactive microglia are shown to
be responsible for the increased neuroinflammation and subsequent neuronal loss and disease progression in these patients.
Orpheris have developed a rich pipeline of therapeutic candidates targeting multiple pathways believed to be responsible for driving microglia activation and disease progression. Each drug candidate is engineered with the hydroxyl dendrimer technology to deliver therapeutic payloads across the blood brain barrier into activated cells with no off-target toxicity.
